These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 37995570)
1. The role of BATF2 deficiency in immune microenvironment rearrangement in cervical cancer - New biomarker benefiting from combination of radiotherapy and immunotherapy. Zong Y; Chang Y; Huang K; Liu J; Zhao Y Int Immunopharmacol; 2024 Jan; 126():111199. PubMed ID: 37995570 [TBL] [Abstract][Full Text] [Related]
3. BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs. Liu Z; Wei P; Yang Y; Cui W; Cao B; Tan C; Yu B; Bi R; Xia K; Chen W; Wang Y; Zhang Y; Du X; Zhou X Clin Cancer Res; 2015 Apr; 21(7):1752-63. PubMed ID: 25762344 [TBL] [Abstract][Full Text] [Related]
4. BATF2 inhibits PD-L1 expression and regulates CD8+ T-cell infiltration in non-small cell lung cancer. Liu J; Li J; Tuo Z; Hu W; Liu J J Biol Chem; 2023 Nov; 299(11):105302. PubMed ID: 37777155 [TBL] [Abstract][Full Text] [Related]
5. STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance. Li T; Zhang W; Niu M; Wu Y; Deng X; Zhou J Front Immunol; 2024; 15():1342647. PubMed ID: 38550593 [TBL] [Abstract][Full Text] [Related]
6. Targeting Batf2 for infectious diseases and cancer. Guler R; Roy S; Suzuki H; Brombacher F Oncotarget; 2015 Sep; 6(29):26575-82. PubMed ID: 26376615 [TBL] [Abstract][Full Text] [Related]
7. Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer. Lin Y; Zhou X; Peng W; Wu J; Wu X; Chen Y; Cui Z BMC Cancer; 2021 Sep; 21(1):1062. PubMed ID: 34565331 [TBL] [Abstract][Full Text] [Related]
8. BATF2 inhibits chemotherapy resistance by suppressing AP-1 in vincristine-resistant gastric cancer cells. Yang W; Zhao S; Wu B; Xu J; Wu Z; Guo J; Zeng R Cancer Chemother Pharmacol; 2019 Dec; 84(6):1279-1288. PubMed ID: 31549215 [TBL] [Abstract][Full Text] [Related]
9. m Xie JW; Huang XB; Chen QY; Ma YB; Zhao YJ; Liu LC; Wang JB; Lin JX; Lu J; Cao LL; Lin M; Tu RH; Zheng CH; Huang CM; Li P Mol Cancer; 2020 Jul; 19(1):114. PubMed ID: 32650804 [TBL] [Abstract][Full Text] [Related]
10. BATF2 balances the T cell-mediated immune response of CADM with an anti-MDA5 autoantibody. Li C; Liu M; Liu K; Li M; Liu Y; Li T; Wei Y; Long Y; He W; Shi X; Li Y; Zhang H Biochem Biophys Res Commun; 2021 Apr; 551():155-160. PubMed ID: 33740622 [TBL] [Abstract][Full Text] [Related]
11. Decreased expression of BATF2 is significantly associated with poor prognosis in oral tongue squamous cell carcinoma. Wen H; Chen Y; Hu Z; Mo Q; Tang J; Sun C Oncol Rep; 2014 Jan; 31(1):169-74. PubMed ID: 24252932 [TBL] [Abstract][Full Text] [Related]
13. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer. Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842 [TBL] [Abstract][Full Text] [Related]
14. Effect of immunotherapy on the immune microenvironment in advanced recurrent cervical cancer. Chen R; Yang W; Li Y; Cheng X; Nie Y; Liu D; Wang H Int Immunopharmacol; 2022 May; 106():108630. PubMed ID: 35189471 [TBL] [Abstract][Full Text] [Related]
15. Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma. Ma H; Liang X; Chen Y; Pan K; Sun J; Wang H; Wang Q; Li Y; Zhao J; Li J; Chen M; Xia J Int J Cancer; 2011 Feb; 128(4):771-7. PubMed ID: 20473897 [TBL] [Abstract][Full Text] [Related]
16. BATF2 prevents T-cell-mediated intestinal inflammation through regulation of the IL-23/IL-17 pathway. Kayama H; Tani H; Kitada S; Opasawatchai A; Okumura R; Motooka D; Nakamura S; Takeda K Int Immunol; 2019 May; 31(6):371-383. PubMed ID: 30753547 [TBL] [Abstract][Full Text] [Related]
17. Batf2/Irf1 induces inflammatory responses in classically activated macrophages, lipopolysaccharides, and mycobacterial infection. Roy S; Guler R; Parihar SP; Schmeier S; Kaczkowski B; Nishimura H; Shin JW; Negishi Y; Ozturk M; Hurdayal R; Kubosaki A; Kimura Y; de Hoon MJ; Hayashizaki Y; Brombacher F; Suzuki H J Immunol; 2015 Jun; 194(12):6035-44. PubMed ID: 25957166 [TBL] [Abstract][Full Text] [Related]
18. Influence of chemoradiation on the immune microenvironment of cervical cancer patients. Herter JM; Kiljan M; Kunze S; Reinscheid M; Ibruli O; Cai J; Niu L; Heßelmann I; Trommer M; Herter-Sprie GS; Köhler C; Marnitz S Strahlenther Onkol; 2023 Feb; 199(2):121-130. PubMed ID: 36251031 [TBL] [Abstract][Full Text] [Related]
19. The tumor-suppressive role of BATF2 in esophageal squamous cell carcinoma. Han T; Wang Z; Yang Y; Shu T; Li W; Liu D; Li P; Qi R; Ren Y; Li L; Liu H; Zhang S; Zhang L Oncol Rep; 2015 Sep; 34(3):1353-60. PubMed ID: 26135942 [TBL] [Abstract][Full Text] [Related]
20. The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial. Li R; Liu Y; Yin R; Yin L; Li K; Sun C; Zhou Z; Li P; Tong R; Xue J; Lu Y Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1432-1441. PubMed ID: 33713744 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]